MGUS è un concetto evidence-based?

Kyle RA (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 6:814–826

Kyle RA, Durie BG, Rajkumar SV et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127

Cinquanta L, Tani M, Sorrentino MC et al. (2017) Percorso di laboratorio raccomandato nella diagnosi, prognosi e follow-up delle gammopatie monoclonali. Riv Ital Med Lab 13:10–23

Kyle RA, Therneau TM, Rajkumar SV et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569

Kyle RA (1989) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Eur J Haematol Suppl 51:70–75

Kyle RA (1994) The monoclonal gammopathies. Clin Chem 40:2154–2161

Kyle RA, Therneau TM, Rajkumar SV et al. (2004) Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 79:859–866

Therneau TM, Kyle RA, Melton LJ et al. (2012) Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 87:1071–1079

Turesson I, Kovalchik SA, Pfeiffer RM et al. (2014) Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123:338–345

Pérez-Persona E, Vidriales MB, Mateo G et al. (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110:2586–2592

Kyle RA, Therneau TM, Rajkumar SV et al. (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369

Rajkumar SV, Kyle RA, Therneau TM et al. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812–817

Kyle RA, Rajkumar SV (2006) Monoclonal gammopathy of undetermined significance. Br J Haematol 134:573–589

Fouquet G, Amouzou K, Renaud L et al. (2015) Les gammapathies monoclonales de signification indéterminée ne nécessitent pas systématiquement un recours à une consultation spécialisée. Rev Méd Interne 36:444–449

Murray DL, Seningen JL, Dispenzieri A et al. (2012) Laboratory persistence and clinical progression of small monoclonal abnormalities. Am J Clin Pathol 138:609–613

AIOM (2016) Linee Guida Mieloma. Edizione 2016. http://www.aiom.it/professionisti/documenti%2Dscientifici/linee%2dguida/1,413,1,#TopList (Accesso 4 settembre 2017)

http://bestpractice.bmj.com/best-practice/monograph/1173/highlights/overview.html (Accesso 4 settembre 2017)

Van de Donk NW, Mutis T, Poddighe PJ et al. (2016) Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol 38(Suppl 1):110–122

Rosiñol L, Bladé J, Esteve J et al. (2003) Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 123:631–636

Mateos MV, Hernández M-T, Giraldo P et al. (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438–447

Rajkumar SV, Dimopoulos MA, Palumbo A et al. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548

Mangiacavalli S, Cocito F, Pochintesta L et al. (2013) Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol 91:356–360

Dhodapaker MV (2016) MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128:2599–2606

Glavey SV, Leung N (2016) Monoclonal gammopathy: the good, the bad and the ugly. Blood Rev 30:223–231

Sigurdardottir EE, Turesson I, Lund SH et al. (2015) The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol 1:168–174

Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125:3049–3058

Walker BA, Wardell CP, Melchor L et al. (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28:384–390

Johnsen HE, Bøgsted M, Schmitz A et al. (2016) The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica 101:1451–1459

Mikulasova A, Wardell CP, Murison A et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617–1625

Radl J (1990) Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol Today 11:234–236

Landgren O, Kyle RA, Pfeiffer RM et al. (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417

Weiss BM, Abadie J, Verma P et al. (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422

Kyle RA, Rajkumar SV (2015) Monoclonal gammopathy of undetermined significance and multiple myeloma. JAMA Oncol 1:174–175

Go RS, Gundrum JD, Neuner JM (2015) Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk 15:177–186

Bianchi G, Kyle RA, Colby CL et al. (2010) Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma related complications. Blood 116:2019–2025